SiSaf Closes $4.3M Series A2 Interim Funding Round

SiSaf, a Belfast and Guildford, UK-based biopharmaceutical company, closed a $4.3m A2 Interim funding round.

The round was led by Vickers Venture Partners, with participation from Invest NI and Innovation Ulster Limited.

Led by Founder and (ProSilic) inventor Dr. Suzanne Saffie-Siebert, Ph.D, SiSaf is a commercial stage bio-pharmaceutical company developing drugs using bio-courier technology, ProSilic®, a novel method of drug delivery that is based on a patented hybrid of porous silicon and liposomes.
An extremely wide range of molecules can be formulated with ProSilic for improved stability, solubility, bioavailability, release and route of administration.

The company intends to use the funds to drive pipeline development and manufacturing capability in dermatology, cosmetic skin care and other therapeutic areas.



Join the discussion